CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III Randomized Controlled Trial of Disitamab Vedotin (DV) Combined With Bacillus Calmette-Guérin (BCG) in BCG-Naïve Patients With HER2-Expressing, High-Risk Non-Muscle-Invasive Bladder Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07207824
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:12.654839+00:00
Published At: 2025-10-06T00:00:00+00:00
Record Updated At: 2025-10-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Bladder (Urothelial, Transitional Cell) Cancer", "NMIBC"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-06"
protocolSection.identificationModule.nctId: "NCT07207824"
protocolSection.identificationModule.officialTitle: "A Phase III Randomized Controlled Trial of Disitamab Vedotin (DV) Combined With Bacillus Calmette-Gu\u00e9rin (BCG) in BCG-Na\u00efve Patients With HER2-Expressing, High-Risk Non-Muscle-Invasive Bladder Cancer"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.